Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

NCT00986154 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00986154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00986154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2009
Completion date
April 30, 2013
Enrollment
8,292 (actual)
Sites
454

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis (dvt), pulmonary embolism (pe), thromboembolism, venous thromboembolism, venous thrombosis